Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.43 |
| ▸ | NPC1 | O15118 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673583 | 0.80 | CASR (0.46) | RAB9ANPC1ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL2507049 | 0.79 | HTT (0.49) | RAB9ANPC1ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL31385157 | 0.74 | RAB9A (0.47) | RAB9ANPC1ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL3678850 | 0.74 | RAB9A (0.44) | RAB9ANPC1ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL25339870 | 0.71 | RAB9A (0.47) | RAB9ANPC1ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL29895658 | 0.69 | RAB9A (0.46) | RAB9ANPC1ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL29690499 | 0.69 | NPC1 (0.48) | RAB9ANPC1ALDH1A1CYP2C19DYRK1A | |
| SCHEMBL30034871 | 0.69 | NPC1 (0.48) | RAB9ANPC1ALDH1A1CYP2C19DYRK1A | |
| SCHEMBL26910775 | 0.69 | RAB9A (0.46) | RAB9ANPC1ALDH1A1CYP2C19CYP1A2 | |
| SCHEMBL30036653 | 0.68 | NPC1 (0.50) | RAB9ANPC1ALDH1A1CYP2C19DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| EP-2376475-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica N.V. (BE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068663-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068663-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | RAB9A 3790/4885NPC1 939/4885ALDH1A1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.